TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07900867: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SSGJ-626 in Participants With Active Cutaneous Lupus Erythematosus

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 140 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT07900867 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07900867 Rescue Dossier →